Category: Editors’ Pick

Ground Beef Recall, Over 120,000 Pounds, Due To E. Coli Concerns

Routine U.S. Department of Agriculture’s (USDA’s) Food Safety and Inspection Service (FSIS) testing found E. coli O103 in a Lakeside Refrigerated Services facility.

Health AI Startup Biofourmis Hits $1.3 Billion Valuation With Series D Funding

Omar Ishrak, chairperson of Intel and former CEO of Medtronic, will join the company’s board as it scales up digital therapeutics trials and care at home programs.

With $35 Million In Funding, Waltz Health Aims To Lower Drug Prices Working With – Not Against – The System

Investors are banking industry veteran Mark Thierer and his data scientist son Jonathon can thread the needle.

NexHealth Hits $1 Billion Valuation In Bid To Rewire Healthcare Data Flow

Under 30 cofounders Alamin Uddin and Waleed Asif have raised $125 million to make it easier for doctors and dentists to digitize their practices and for developers to access that data.

InnovationRx: Hospital Ownership Data; Plus, Novavax Reveals Covid/Flu Vaccine Preliminary Results

InnovationRx is your weekly digest of healthcare news. Sign up!

Novavax Claims Positive Results From Early Trials Of Combination Covid/Flu Vaccine

The company will be moving into more clinical trials for the vaccine through 2022 and 2023.

Leadership From Both Parties Is Needed To Respond To The Next Phase Of The Covid Pandemic

Dr. Anand Parekh, chief medical advisor for the Bipartisan Policy Center, discusses what political leaders need to do in order to guide the country through the next few months of the Covid pandemic.

Meet The Founders Of The $2.7 Million Startup Behind The New Covid Breathalyzer

InspectIR’s device, originally developed to detect if people were using marijuana, just received FDA authorization as a Covid test.

InnovationRx: AI In Healthcare; Plus, Return Of The Mask?

InnovationRx is your weekly digest of healthcare news. Sign up!

New Evidence That Psilocybin May ‘Rewire’ Brain To Help Those With Depression

A study found that people with depression who took two doses of psilocybin, the active ingredient in psychedelic mushrooms, experienced not only an improvement in their symptoms but also “increased global integration in the brain.